Cited 2469 times in
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2019-09-20T07:41:39Z | - |
dc.date.available | 2019-09-20T07:41:39Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171016 | - |
dc.description.abstract | BACKGROUND: First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. METHODS: This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater. Randomisation was computer generated, accessed via an interactive voice-response and integrated web-response system, and stratified by region of enrolment (east Asia vs rest of world), ECOG performance status score (0 vs 1), histology (squamous vs non-squamous), and PD-L1 TPS (≥50% vs 1-49%). Enrolled patients were randomly assigned 1:1 in blocks of four per stratum to receive pembrolizumab 200 mg every 3 weeks for up to 35 cycles or the investigator's choice of platinum-based chemotherapy for four to six cycles. Primary endpoints were overall survival in patients with a TPS of 50% or greater, 20% or greater, and 1% or greater (one-sided significance thresholds, p=0·0122, p=0·0120, and p=0·0124, respectively) in the intention-to-treat population, assessed sequentially if the previous findings were significant. This study is registered at ClinicalTrials.gov, number NCT02220894. FINDINGS: From Dec 19, 2014, to March 6, 2017, 1274 patients (902 men, 372 women, median age 63 years [IQR 57-69]) with a PD-L1 TPS of 1% or greater were allocated to pembrolizumab (n=637) or chemotherapy (n=637) and included in the intention-to-treat population. 599 (47%) had a TPS of 50% or greater and 818 patients (64%) had a TPS of 20% or greater. As of Feb 26, 2018, median follow-up was 12·8 months. Overall survival was significantly longer in the pembrolizumab group than in the chemotherapy group in all three TPS populations (≥50% hazard ratio 0·69, 95% CI 0·56-0·85, p=0·0003; ≥20% 0·77, 0·64-0·92, p=0·0020, and ≥1% 0·81, 0·71-0·93, p=0·0018). The median surival values by TPS population were 20·0 months (95% CI 15·4-24·9) for pembrolizumab versus 12·2 months (10·4-14·2) for chemotherapy, 17·7 months (15·3-22·1) versus 13·0 months (11·6-15·3), and 16·7 months (13·9-19·7) versus 12·1 months (11·3-13·3), respectively. Treatment-related adverse events of grade 3 or worse occurred in 113 (18%) of 636 treated patients in the pembrolizumab group and in 252 (41%) of 615 in the chemotherapy group and led to death in 13 (2%) and 14 (2%) patients, respectively. INTERPRETATION: The benefit-to-risk profile suggests that pembrolizumab monotherapy can be extended as first-line therapy to patients with locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK alterations and with low PD-L1 TPS. FUNDING: Merck Sharp & Dohme. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | Lancet | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anaplastic Lymphoma Kinase/drug effects | - |
dc.subject.MESH | Anaplastic Lymphoma Kinase/genetics | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/administration & dosage | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/adverse effects* | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/therapeutic use | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | - |
dc.subject.MESH | B7-H1 Antigen/metabolism* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/drug therapy* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/metabolism | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/pathology | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung/secondary* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Far East/epidemiology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genes, erbB-1/drug effects | - |
dc.subject.MESH | Genes, erbB-1/genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/metabolism | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Lung Neoplasms/secondary | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Metastasis/pathology | - |
dc.subject.MESH | Translocation, Genetic | - |
dc.title | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Tony S K Mok | - |
dc.contributor.googleauthor | Yi-Long Wu | - |
dc.contributor.googleauthor | Iveta Kudaba | - |
dc.contributor.googleauthor | Dariusz M Kowalski | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Hande Z Turna | - |
dc.contributor.googleauthor | Gilberto Castro | - |
dc.contributor.googleauthor | Vichien Srimuninnimit | - |
dc.contributor.googleauthor | Konstantin K Laktionov | - |
dc.contributor.googleauthor | Igor Bondarenko | - |
dc.contributor.googleauthor | Kaoru Kubota | - |
dc.contributor.googleauthor | Gregory M Lubiniecki | - |
dc.contributor.googleauthor | Jin Zhang | - |
dc.contributor.googleauthor | Debra Kush | - |
dc.contributor.googleauthor | Gilberto Lopes | - |
dc.identifier.doi | 10.1016/S0140-6736(18)32409-7 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02152 | - |
dc.identifier.eissn | 1474-547X | - |
dc.identifier.pmid | 30955977 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0140673618324097 | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 393 | - |
dc.citation.number | 10183 | - |
dc.citation.startPage | 1819 | - |
dc.citation.endPage | 1830 | - |
dc.identifier.bibliographicCitation | Lancet, Vol.393(10183) : 1819-1830, 2019 | - |
dc.identifier.rimsid | 64409 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.